You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME

Improving Recognition and Awareness of Novel Therapeutics for Batten Disease

  • Authors: Angela Schulz, MD, PhD
  • CME Released: 9/21/2021
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 9/21/2022
Start Activity


Target Audience and Goal Statement

This activity is intended for neurologists, pediatricians, pediatric neurologists, medical geneticists, and other clinicians who diagnose and treat patients with Batten disease.

The goal of this activity is to improve clinicians’ knowledge of factors that differentiate subtypes of Batten disease and clinical data for therapies being studied for the management of Batten disease.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Factors that differentiate subtypes of Batten disease
    • Clinical data for therapies being studied for the management of Batten disease


Disclosures

As an organization accredited by the ACCME, Medscape, LLC requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • Angela Schulz, MD, PhD

    Assistant Professor of OB/GYN and Reproductive Biology
    Children’s Hospital
    NCL Specialty Clinic
    International Center of Lysosomal Storage Disorders (ICLD)
    University Medical Center Hamburg-Eppendorf
    Hamburg, Germany

    Disclosures

    Disclosure: Angela Schulz, MD, PhD, has the following relevant financial relationships: 
    Advisor or consultant for: Amicus Therapeutics; BioMarin; Neurogene; REGENXBIO
    Grants for clinical research from: BioMarin, REGENXBIO

Editors

  • Pakinam Aboulsaoud, PharmD

    Medical Education Director, Medscape, LLC

    Disclosures

    Disclosure: Pakinam Aboulsaoud, PharmD, has disclosed no relevant financial relationships.

  • Christina T. Loguidice

    Freelance Medical Writer

    Disclosures

    Disclosure: Christina T. Loguidice has disclosed no relevant financial relationships.

CME Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline

None of the nonfaculty planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Improving Recognition and Awareness of Novel Therapeutics for Batten Disease

Authors: Angela Schulz, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 9/21/2021

Valid for credit through: 9/21/2022

processing....

Pre-Assessment Survey

Before you begin, please take this brief survey.

  • Print